Phenotypic Drug Discovery Resource

Background

Phenotypic drug discovery involves searching for agents that change cell function and is a common method for lead discovery in drug development. To do this, the collaborative team screened part of the NCATS Pharmaceutical Collection (NPC), which includes 3,800 approved and investigational medicines, against the OIDD assay panel, which was offered through Lilly’s OIDD platform. The OIDD testing panel consisted of assays relevant to Lilly’s areas of focus, such as cardiovascular diseases, diabetes, cancer and endocrine disorders, and was designed to help researchers uncover new starting points for early drug discovery.

Testing approved drugs in the OIDD assay panel broadens scientific knowledge of the biology of these compounds. Results from this effort may enable researchers to better predict treatment outcomes, design new drug combinations, and potentially reveal new uses for existing drugs, a time- and cost-saving approach called repurposing.

Testing approved drugs in the OIDD assay panel broadens scientific knowledge of the biology of these compounds. Results from this effort may enable researchers to better predict treatment outcomes, design new drug combinations, and potentially reveal new uses for existing drugs, a time- and cost-saving approach called repurposing. Results from nearly 2,500 of the NPC compounds are available online. These experiments are described in detail in a paper published July 15, 2015, in PLOS One.

Access the Data*

Choose a data format:

1. Processed CSV data files and individual assay datasets
2. Raw data
3. Data in the format of a Semantic Knowledge Network

*Data files last updated January 2016.

Download CSV Data Files and Sets

• Compound meta data (CSV - 294KB) 
• Assay experiment results (CSV - 4MB) 

Access individual assay datasets via PubChem AID 1117321.

Download Raw Data

• Well_level_data_10022014_with_pubchem_info (TXT - 13MB): This file contains experimental data for each individual plate well, normalized between 0 and 100 percent using negative and positive controls, respectively. For screening assays, it contains one row for each screening result (each unique combination of assay, compound, concentration and run date). For concentration-response assays, it contains 10 rows for each experiment (each unique combination of assay, compound and run date). The 10 concentrations analyzed as a dose-response experiment share a common value for the CALC_RESULT_ID field. Screening results do not have CALC_RESULT_ID defined because those results are not analyzed via dose-response curves.
• Curve_fit_results_10022014_with_pubchem_info (TXT - 684KB): This file contains the IC50 values created by fitting concentration response curve data from the file above. Users can align results from both files via the CALC_RESULT_ID field.

Download OIDD Semantic Knowledge Network Data

The OIDD Semantic Knowledge Network encodes the experimental relationship between NPC compounds and OIDD assays in a standardized format that can be exported into other databases and information sources. Similarly, it also encodes relationships between compounds and assays and among other experimental data, including ChEMBL dataset mapping and classification of assays using the bioassay ontology (BAO).

Users can download Semantic Knowledge Network data represented as resource description format (RDF) and save in the Turtle (.ttl) format. The beta release of these files, which includes everything in the first table below, provides the default graph of a knowledge network and one Web ontology language (OWL) file comprising one BAO module. In addition to the OIDD phenotypic assay data, protein targets and bioactivity associations from the ChEMBL database are included to facilitate queries that integrate phenotypic and biochemical data.

• Semantic Knowledge Network data (ZIP - 2MB)

Field Descriptions for CSV Data Files

Compound Meta Data

Assay Meta Data

Assay Result Meta Data